close

Fundraisings and IPOs

1 62 63 64 65 66 74
Number of results: 1471
Date Company Amount Funding type Investors Therapeutic area Type of Information
2012-04-03 Genfit (France) €600 K private placement Yorkville Advisors LLC (USA) Cardiovascular diseases - Metabolic diseases - Liver diseases Private placement
2012-03-30 Immunogenes (Switzerland - Hungary) CHF 1 million (€0.83 million) financing round LSWorks LLC (USA)
PolyTechnos Venture Partners (Germany)
majority of the company’s existing investors
Technology - Services Fundraising
2012-03-29 Thrombogenics (Belgium) €77.8 million private placement domestic and international investors - undisclosed qualified institutional buyers in the United States Ophtalmological diseases Private placement
2012-03-28 Promethera Biosciences (Belgium) € 23.6 million ($31.4 million) series B financing round Boehringer Ingelheim Venture Fund (Germany)
Shire (UK)
Mitsui Global Investment (Japan)
ATMI (USA)
SambrInvest (Belgium)
Walloon Region (Belgium)
Regenerative medicine - Liver diseases Fundraising
2012-03-28 DBV Technologies (France) €40.5 million initial public offering (IPO) The French Strategic Investment Fund (Fonds stratégique d\'investissement - FSI) has taken a stake in DBV Technologies by investing 15 € million euros as part of the offer. The FSI is holding 12.6%% of its capital.

Allergic diseases - Immunological diseases IPO
2012-03-26 ADC Therapeutics (Switzerland) $50 million (€37.4 million) fundraising Celtic Therapeutics (USA-UK-Switzerland) - co-founders of Spirogen (UK) - Cancer Research Technology (UK) Cancer - Oncology Fundraising
2012-03-22 Enterome Bioscience (France) €5 million series A financing round Seventure Partners (France) - Lundbeckfond Ventures (Denmark) Digestive diseases - Inflammatory diseases Fundraising
2012-03-21 Novasep (France) € 33 million private placement FSI (France) - Azulis (France) Technology - Services Private placement
2012-03-13 Hybrigenics (France) € 3.3 million private placement Cancer - Oncology - Technology - Services Private placement
2012-03-06 Numab (Switzerland) CHF 895 000 (€ 742 604) grant Swiss Commission for Technology and Innovation (CTI) (Switzerland) Grant
2012-03-06 Telormedix (Switzerland) CHF 1.37 Million grant CTI/KTI Programme (Switzerland) Cancer - Oncology - Inflammatory diseases Grant
2012-03-06 Lanthio Pharma (The Netherlands) €180,000 grant European Eurostars Programme (EU) Technology - Services Grant
2012-03-05 Medicyte (Germany) PRIMACYT (Germany) €300 000 grant Federal Ministry of Education and Research (BMBF) (Germany) Regenerative medicine - Liver diseases Grant
2012-03-05 Exonhit (France) €418,000 grant Cancer - Oncology Grant
2012-03-05 AB Science (France) €10 million Cancer - Oncology - Autoimmune diseases - Neurodegenerative diseases Establishment of a new subsidiary in the EU
2012-02-28 BiolineRx (Israel) $15 million (€ 11.2 million) private placement healthcare-focused U.S. institutional investors Private placement
2012-02-16 Protalix (Israel) $24.75 million (€18.8 million) private placement Rare diseases - Genetic diseases Private placement
2012-02-14 Adocia (France) € 25.3 million (increased to €27.36 million following partial exercise of over-allotment option) IPO Metabolic diseases IPO
2012-02-13 Innavirvax (France) € 3.7 million financing round Pradeyrol Développement(France)
Fa Dièse (France)
FRCI (Fonds Régional de Co-Investissement d’Ile-de-France) (France)
Cap Decisif 2 (France)
G1J (France)
Infectious diseases Fundraising
2012-02-13 Effimune (formerly TcL Pharma) (France) and the TRIAD consortium €3 million grant Autoimmune diseases Grant